P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy
Sponsor: American Epilepsy Society
Terminated
PI left the institution.
Other Epilepsy trials with similar outcome
A PHASE2/PHASE3 clinical study on Epilepsy, this trial is terminated or withdrawn. The trial is conducted by American Epilepsy Society and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2022 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — Oct 2022 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Epilepsy Society
- Columbia University
- GlaxoSmithKline
- Milken Institute
For direct contact, visit the study record on ClinicalTrials.gov .